Prosecution Insights
Last updated: November 06, 2026
Application No. 18/496,727

PTH Compounds with Low Peak-To-Trough Ratios

Final Rejection §102§112§DOUBLEPATENT
Filed
Oct 27, 2023
Priority
Sep 29, 2016 — EU 16191454.4 +4 more
Examiner
BRADLEY, CHRISTINA
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ascendis Pharma Bone Diseases A/S
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
651 granted / 1040 resolved
+2.6% vs TC avg
Strong +33% interview lift
Without
With
+33.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
62 currently pending
Career history
1111
Total Applications
across all art units

Statute-Specific Performance

§101
6.0%
-34.0% vs TC avg
§103
28.9%
-11.1% vs TC avg
§102
21.5%
-18.5% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1040 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Applicant’s claim for the benefit of foreign priority under 35 U.S.C. 119 (a)-(d)is acknowledged. The disclosure of the prior-filed applications, Application Nos. EP16191454.4, EP17155846.3, PCT/EP2017/074594, 16/337,955, and 18/053,701 provides adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for the claims as amended July 22, 2026. The earliest effective filing date of claims 1, 6-7 and 17-19 is the filing date of Application Nos. EP16191454.4, September 29, 2016. Claim Rejections - 35 USC § 112 - withdrawn The rejections under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement and enablement requirement are withdrawn in view of the amendment filed July 22, 2026. Claim Rejections - 35 USC § 102 - withdrawn The rejections under 35 U.S.C. 102(a)(1) over WO 2017/148883 A1, WO 2018/060310, WO 2018/060311 A1, and WO 2020/165087 A1 (published August 20, 2020) are withdrawn. The references no longer qualify as prior art because of the perfected priority claim of the instant claims. Double Patenting - withdrawn The terminal disclaimers filed July 22, 2026, are sufficient to overcome the nonstatutory double patenting rejections over: U.S. Patent No. 11,590,207; U.S. Patent No. 11,890,326; U.S. Patent No. 11,918,628; U.S. Patent No. 12,295,989; copending Application No. 19/077,517; U.S. Patent No. 12,403,182; U.S. Patent No. 12,453,778; and copending Application No. 19/354,691. The claim amendments and arguments filed July 22, 2026, are sufficient to overcome the nonstatutory double patenting rejections over: U.S. Patent No. 11,793,861; U.S. Patent No. 12,214,020 ; copending Application No. 19/279,831; and copending Application No. 19/396,182. Double Patenting - maintained Claims 1, 6-7, and 17-19 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 11,759,504. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims anticipate the instant claims. This rejection was not traversed in the response filed July 22, 2026, and a terminal disclaimer was not filed. Reference claim 1 recites a pharmaceutical composition comprising a parathyroid hormone (PTH) compound, wherein the pharmaceutical composition is suitable for subcutaneous administration, and wherein after subcutaneous administration to a mammal the PTH compound has a pharmacokinetic profile exhibiting a peak to trough ratio of free PTH of less than 4 in plasma within one daily injection interval at steady state; wherein the PTH compound is a water-soluble controlled-release PTH compound of formula (Ia) or a pharmaceutically acceptable salt thereof Z-(L2-L1-D), wherein -D is a PTH moiety, which has the sequence of SEQ ID NO:51; -L2-L1- has the formula: PNG media_image1.png 70 257 media_image1.png Greyscale wherein the unmarked dashed line indicates the attachment to a nitrogen of -D by an amide bond; and the dashed line marked with an asterisk indicates attachment to Z; Z comprises a polyethylene glycol polymer of about 40 kDa; x is 1; and the PTH moiety is released with a release half-life of at least 12 hours. Z comprises a polyethylene glycol polymer of about 40 kDa wherein the PEG is branched, as required by instant claim 1. A claim to a method of using a composition is not patentably distinct from an earlier claim to the identical composition in a patent disclosing the identical use (Sun Pharmaceutical. Industries, Ltd. v. Eli Lilly & Co., 611 F.3d 1381 (Fed. Cir. 2010)). In the instant case, the reference patent discloses a method of treating hypoparathyroidism with the claimed composition (col 3). Therefore, claim 1 is not patentably distinct from the reference claim. Regarding claims 5-6, reference claim 3 requires that administration is subcutaneous injection with a pen device. With respect to claim 7, reference claim 4 requires that the peak to trough ratio is less than 3. Regarding claims 17-18, reference claim 8 requires that the pharmaceutical composition has a pH ranging from and including pH 4 to pH 5. Regarding claim 19, a polyethylene glycol polymer of about 40 kDa corresponds to m and p ranging from 400 to 500. Claims 1, 6-7, and 17-19 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 11,857,603. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims anticipate the instant claims. This rejection was not traversed in the response filed July 22, 2026, and a terminal disclaimer was not filed. Reference claim 1 recites method of treating a human patient having hypoparathyroidism comprising subcutaneously administering a pharmaceutical composition comprising a parathyroid hormone (PTH) compound, wherein the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one administration interval at a steady state; wherein the PTH compound is a water-soluble controlled-release PTH compound of formula (Ia) or a pharmaceutically acceptable salt thereof Z-(L2-L1-D), wherein -D is a PTH moiety, which has the sequence of SEQ ID NO:51; -L2-L1- has the formula: PNG media_image1.png 70 257 media_image1.png Greyscale wherein the unmarked dashed line indicates the attachment to a nitrogen of -D by an amide bond; and the dashed line marked with an asterisk indicates attachment to Z; Z is PNG media_image2.png 118 654 media_image2.png Greyscale wherein the dashed line indicates attachment to -L2 and m and p are independently 150-1000; and the PTH moiety is released with a release half-life of at least 12 hours. Reference claim 3 requires that the administration interval is 24 hours. Reference claim 5 requires that the administration is subcutaneous injection. With respect to claim 6, reference claim 6 requires that administration is subcutaneous injection with a pen device. With respect to claim 7, reference claim 7 requires that the peak to trough ratio is less than 3. Regarding claims 17-18, reference claim 9 requires that the pharmaceutical composition has a pH ranging from and including pH 4 to pH 5. Regarding claim 19, reference claim 10 requires m and p are independently 400-500. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINA M MARCHETTI BRADLEY whose telephone number is (571)272-9044. The examiner can normally be reached Monday-Friday, 8:30 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G Garyu can be reached at (571) 270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CHRISTINA M MARCHETTI BRADLEY Primary Examiner Art Unit 1654 /CHRISTINA M MARCHETTI BRADLEY/Primary Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

Oct 27, 2023
Application Filed
Apr 22, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT
Jul 22, 2026
Response Filed
Oct 06, 2026
Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779017
EXENATIDE ANALOG
4y 7m to grant Granted Nov 03, 2026
Patent 12780893
CONFORMATIONALLY CONSTRAINED GLUCAGON ANALOGUES AND THEIR USE IN GLUCAGON-SINGLE CHAIN INSULIN FUSION PROTEINS
3y 2m to grant Granted Nov 03, 2026
Patent 12779012
KEAP1/NRF2 PROTEIN-LIKE POLYMERS
3y 1m to grant Granted Nov 03, 2026
Patent 12760067
PEPTIDES FOR USE IN SKIN AND HAIR PIGMENTATION
3y 5m to grant Granted Oct 13, 2026
Patent 12758482
COMPOSITIONS AND METHODS RELATING TO STIMULATION OF HYALURONIC ACID
3y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
96%
With Interview (+33.3%)
2y 8m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1040 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month